The reason why the growth stocks do so much better is that they seem to show gains in value in the hundreds of percent each decade. In contrast, it is an unusual bargain that is as much as 50 percent undervalued. The cumulative effect of this simple arithmetic should be obvious. – Philip Fisher (the Father of Growth Investing)
On Jan 05, 2018, the share price of Crispr Therapeutics (NASDAQ:CRSP), a bioscience focusing on gene-editing and CAR-T to treat serious conditions such as cancers and genetic diseases, continued its rally. The stock added another $2.90 (over 12% profits) to value at $26.81 for the said trading session. Since we recommended the company on Nov. 27, 2017 (just over a month) to subscribers of Integrated BioSci Investing, the stock added another $7.26 (or 37% in capital appreciation). This robust run-up is interesting because, on Jan. 04, 2018, the company announced that the 5M additional common shares issued on Jan 03 will be priced at $22.75.
Hot Undervalued Stocks For 2019: Masimo Corporation(MASI)
- [By Keith Speights, Sean Williams, and Cory Renauer]
So when we asked three of our top healthcare contributors to name three of the best stocks to invest in healthcare, it’s not surprising that their responses listed companies in three different industries: medical device makerMasimo (NASDAQ:MASI), pharmacy services giant CVS Health (NYSE:CVS) and biopharmaceutical company Ligand Pharmaceuticals (NASDAQ:LGND). Here’s why these three healthcare stocks stand out as smart picks.
Hot Undervalued Stocks For 2019: Huntington Bancshares Incorporated(HBAN)
- [By Ben Levisohn]
Who is at the lower-end of the range for 2016 payout ratios? We expect Zions Bancorporation, Huntington Bancshares (HBAN), andBank of America to seek the least amount of capital return in 2016 (ranging between 50-60% of estimated earnings).
Hot Undervalued Stocks For 2019: Universal Health Services, Inc.(UHS)
- [By Ben Levisohn]
Universal Health Services (UHS), yesterday’s biggest loser, soared to the top of the S&P 500 today as it rebounded from the massive selloff.
Agence France-Presse/Getty Images
Universal Health Servicesgained 6.9% to $108.57 today, while the S&P 500 rose 0.4% to 2,262.03.
Weakness in Universal Health Services began when Buzzfeed ran an article last week, contending the companys psychiatric hospitals put profits ahead of people. Yesterday, it tumbled when Raymond James cut its rating on the stock due to problems that could be caused by a potential Senate investigation.
Universal Health Services’ market capitalization rose to $10.5 today from $9.8 billion yesterday, nearly recouping its drop from $10.6 billion on Dec. 13.
It reported net income of $680 million on sales of $9 billion in 2015.
- [By Benzinga News Desk]
Goldman Sachs (NYSE: GS) has at least one billion reasons to hope President Trump’s paring back of Dodd-Frank will include the Volcker Rule: Link
10:30 a.m. Dallas Fed Manufacturing Business Index
11:30 a.m. 6-Month Bill Auction
11:30 a.m. 3-Month Bill Auction
1 p.m. 2-Year Note Auction
1:15 p.m. Chicago Fed President Evans Speaks
6:30 p.m. FOMC Member Kaplan Speaks
Piper Jaffray upgraded Best Buy Co (NYSE: BBY) from Neutral to Overweight
Wells Fargo upgraded Allscripts Healthcare (NASDAQ: MDRX) from Market Perform to Outperform
Mizuho upgraded Universal Health Service (NYSE: UHS) from Neutral to Buy
Piper Jaffray downgraded The Michaels Companies (NASDAQ: MIK) from Overweight to Neutral
JMP Securities downgraded KB Home (NYSE: KBH) from Market Outperform to Market Perform
Raymond James downgraded Sierra Wireless Inc. (NASDAQ: SWIR) from Outperform to Market Perform
This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here or email firstname.lastname@example.org.
- [By Paul Ausick]
Universal Health Services Inc. (NYSE: UHS) lost 8.4% Wednesday to post a new 52-week low of $1/99.81 after closing Tuesday at $108.99. The 52-week high is $139.77. Volume of around 5.8 million was nearly 6 times the daily average of around 1 million shares traded. Raymond James downgraded the stock this morning on news of another request for information from the company related to a federal investigation.
- [By Ben Levisohn]
Universal Health Services (UHS) tumbled to the bottom of the S&P 500 today after BuzzFeed published an investigative story alleging that the company’s psychiatric hospitals put profits ahead of people.
Shares of Universal Health Services dropped 12% to$111.30 today, while the S&P 500 rose 1.3% to 2,241.35, a record high.
Universal Health Services’ stock had been minding its business for most of the day–it was up 1.1% at $127.76 at 3:10 p.m. today–when the story by BuzzFeed’s Rosalind Adams went live. Here’s the gist:
Millwood Hospital is part of Americas largest psychiatric hospital chain, Universal Health Services, or UHS. Its more than 200 psychiatric facilities across the country admitted nearly 450,000 patients last year. The result was almost $7.5 billion in revenues from inpatient care last year and profit margins of around 30%. More than a third of the companys overall revenue from both medical hospitals and psychiatric facilities comes from taxpayers through Medicare and Medicaid.
A yearlong BuzzFeed News investigation based on interviews with 175 current and former UHS staff, including 18 executives who ran UHS hospitals; more than 120 additional interviews with patients, government investigators, and other experts; and a cache of internal documents raises grave questions about the extent to which those profits were achieved at the expense of patients.
Universal Health Services market capitalization dropped to $10.7 billion today from $12.3 billion yesterday. It reported net income of $680 million on sales of $9 billion in 2015.
- [By Ben Levisohn]
Universal Health Services (UHS) slumped to the bottom of the S&P 500 today after getting downgraded by Raymond James.
Universal Health Servicesdropped 6.8% to $101.55 today, while the S&P 500 fell 0.8% to 2,253.28.
Raymond James analyst John Ransom and team explain why they cut Universal Health Services to Market Perform from Outperform:
We are lowering our rating onUniversal Health Services to a Market Perform (from an Outperform) due to an escalation in events surrounding last weeks Buzzfeed article. Last Friday (12/9), Senator Grassley, Chair of the Judiciary Committee, sent a letter…to the office of inspector general regarding details of the current federal investigation into Universal Health Services. Specifically, the letter rehashes the Buzzfeed article and requests an update on the investigation by Dec. 23. Our view is that – even ifUniversal Health Services management is correct on the legalities – we think the entrance of the venerable Senator Grassley into the mix takes the political risk to a more dangerous level. Plus – even if “suicide ideation” doesn’t generate additional revenues per admission, we think it’s possible that the heightened political scrutiny could invite more caution and/or red tape into the admissions process – either externally or from self-policing. Add in the ongoing OIG investigation, and we think the risk-reward is no longer compelling.
Universal Health Services’ market capitalization fell to $9.8 billion today from $10.6 billion yesterday. It reported net income of $680 million on sales of $9 billion in 2015.
- [By David Zeiler]
Fear that expense could return if Obamacare is repealed hammered hospital stocks on Nov. 9. HCA Holdings Inc. (NYSE: HCA) fell almost 11%. Universal Health Services Inc. (NYSE: UHS) slipped nearly 7%. And Tenet Healthcare Corp. (NYSE: THC) plummeted almost 25%.
Hot Undervalued Stocks For 2019: Pershing Gold Corporation(PGLC)
- [By Sara Cornell]
Leading the way is CEO Edward Karr. As a founder of Pershing Gold Corp (NASDAQ:PGLC), he currently serves on their Board of Directors, and has been active in the natural resource industry for many years. With a background in finance and investment banking, Karr is credited with raising capital to begin operations at US Gold Corp, and establishing financing for both the operational and exploration sides of the company.
Hot Undervalued Stocks For 2019: Pacira Pharmaceuticals, Inc.(PCRX)
- [By Jon C. Ogg]
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) has found itself in the middle of a great opportunity but not being able to make the last mile of the race. Unfortunately, pain management in a non-opioid treatment has become an elusive target. And it’s too bad when you consider how many people have become addicted to opioids in America.
- [By Chris Lange]
Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) has announced preliminary unaudited total revenues and net product sales for Exparel for the fourth quarter and the full year. Total revenues were $72.9 million and $276.4 million for the fourth quarter and full year, respectively. Exparel net product sales were $71.4 million and $239.9 million for the same periods, respectively. The consensus estimates from Thomson Reuters were calling for revenues of $72.56 million in the fourth quarter and $276.09 million in the full year.
- [By Lisa Levin]
Pacira Pharmaceuticals Inc (NASDAQ: PCRX) shares were also up, gaining 17 percent to $39.80. Pacira Pharmaceuticals reported preliminary 2016 revenue of $276.4 million.